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S U M M A R Y
Background: Leptospirosis is an emerging zoonotic infection worldwide, possibly due to climate change
and demographic shifts. It is regarded as endemic in Sub-Saharan Africa; however, for most countries
scarce epidemiological data, if any, exist. The primary objectives were to describe the prevalence of
leptospirosis in countries in Sub-Saharan Africa, and to develop options for prevention and control in the
future.
Methods: A systematic review was conducted to determine the prevalence of leptospirosis in Sub-
Saharan Africa; the PRISMA guidelines were followed. Medline/PubMed, Embase, The Cochrane Library,
Web of Science, BIOSIS Previews, the African Index Medicus, AJOL, and Google Scholar were searched.
Results: Information about the prevalence and incidence of leptospirosis in humans is available, but
remains scarce for many countries. Data are unavailable or outdated for many countries, particularly
those in Central Africa. Most data are available from animals, probably due to the economic losses caused
by leptospirosis in livestock. In humans, leptospirosis is an important cause of febrile illness in Sub-
Saharan Africa. It concerns numerous serogroups, harboured by many different animal carriers.
Discussion: A wide variety of data was identiﬁed. Prevalence rates vary throughout the continent and
more research, especially in humans, is needed to reliably gauge the extent of the problem. Preventive
measures need to be reconsidered to control outbreaks in the future.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Leptospirosis is a globally important zoonotic disease caused by
host-dependent spirochetes of the genus Leptospira (order
Spirochaetales).1 Humans are usually infected by contact with
urine of an infected host, contaminated drinking water or soil, or
infected animal tissue. Notorious reservoirs are rodents, but
reservoirs include a variety of wild and domestic animals,
livestock, and insectivores. Pathogenic leptospires enter the body
through mucous membranes, conjunctivae, small cuts, abrasions,
and possibly wet skin.2 Leptospires survive longest in warm,
humid, tropical and sub-tropical conditions, but also persist in§ Registration number Prospero: CRD42013006545.
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).temperate regions.3 The known endemicity of human disease is
focused on the Caribbean and Latin America, the Indian subconti-
nent, Southeast Asia, Oceania, and Eastern Europe.4,5 To a lesser
extent, it is endemic in other European countries, such as Denmark,
Greece, Portugal, France, Germany4, and the Netherlands.6
The disease was ﬁrst described by Adolf Weil in 1886, but
leptospires were identiﬁed as the causative organism of Weil’s
disease in Japan in 1908, where it affected coal miners.7 Leptospira
are conventionally divided into two species, the pathogenic
Leptospira interrogans sensu lato and the saprophytic Leptospira
biﬂexa sensu lato. More than 60 serovars have been described in
the latter, and over 250 serovars in 25 serogroups are recognized in
L. interrogans. Different hosts carry distinct serovars.3 Although
this classiﬁcation has been supplemented by a genotypic
classiﬁcation,8 the serological classiﬁcation is commonly used.
Human infection is associated with highly variable clinical
manifestations, ranging from asymptomatic or undifferentiatedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Box 1. Diagnostic methods
In daily practice, diagnosis is predominantly based on sero-
logical testing. There is a leptospiremia during the first 10 days
of the disease3 during which the leptospires can be cultured
from blood or CSF. However, blood culture is insensitive and
isolation of the fastidious leptospires can take weeks to
months.172 Polymerase chain reaction (PCR) is used as stan-
dard molecular diagnostic test in the first week of illness.3 After
about 5 to 10 days leptospires may appear in the urine and
concomitantly, antibodies become detectable in blood and
CSF.3 The most frequently used tests for antibody detection
are the Microscopic Agglutination Test (MAT),173 which is the
reference standard assay, and enzyme-linked immunosorbent
assay (ELISA), introduced in 1984174 (see Box 2). MAT serology
is insensitive, especially in acute-phase specimens and sero-
conversion in fulminantly ill people might not happen before
the patient dies.175 The most likely infective serogroup can be
deduced from the highest titre against one or more sero-
vars,176 but interpretation is complicated by the high degree
of cross-reactions between different serogroups, especially in
acute-phase serum samples.3 IgM detection by ELISA has been
shown to be more sensitive in the acute phase.173,177 MAT,
ELISA, and PCR are expensive, technically demanding and not
widely available and applicable in most settings in sub-
Saharan Africa. Rapid diagnostic tests (RDTs) for antibody
detection are available.177 Three RDTs were recently evaluat-
ed.178 All three had low sensitivity rates based on a single
sample, which substantially increased when the results of
paired subsequent samples were combined, although yielding
lower specificity.
MAT can provide a general impression about which ser-
ogroups circulate within a population,3 but conclusions about
infecting serovars cannot be drawn without isolates. Animals
can be divided in accidental and maintenance hosts: the latter
occurs by persistent colonization of the proximal renal tubules
of carrier hosts. These can remain symptom-free and may
present as seronegatives while excreting leptospires in the
urine for the entire life.2
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rates, like Weil’s disease.2,3 The diagnosis is often missed,
particularly in mild cases, due to unawareness among clinicians
and its broad spectrum of clinical presentations, often mimicking
other infectious diseases. A diagnosis on clinical grounds alone
may be difﬁcult.3,9 A laboratory-based diagnosis is therefore
necessary, but current diagnostic methods are cumbersome.10
Clinical signs, diagnosis and case management, and prevention
and control of leptospirosis, including in Sub-Saharan Africa, are
not the focus of this review and have been covered in detail
elsewhere.2,3,11–14 Although researchers accept the ubiquity of
this zoonosis in Sub-Saharan Africa, the epidemiological pattern
of leptospirosis remains unclear. The aims of this review were (1)
to summarize the available data for leptospirosis from Sub-
Saharan Africa; (2) to gain an insight into the burden of the disease
in the region; and (3) to develop options for prevention and
control in the future.
Leptospirosis as a human disease is a result of a complex
interaction between humans, animal reservoirs, and the envi-
ronment. A study from Vietnam showed that in rural endemic
areas, exposure begins at a young age, with a substantial rate of
seroconversions remaining largely asymptomatic.15 Transmis-
sion in rural areas is related to increased rainfall, livestock
holding, and farming. In urban areas the transmission is usually
rodent-borne and associated with poor hygiene, inadequate
waste disposal, and overcrowding, circumstances typical in urban
slums in the developing world.16 Heavy rainfall and ﬂooding are
often, but not always associated with outbreaks of leptospirosis
around the world.17,18 The global epidemiology of leptospirosis
has been reviewed.4,5 However, data from Sub-Saharan Africa
remain scarce. Africa has the second largest urban growth rate
(0.23 million people per week in the last decade) and subse-
quently high slum growth rates;19 a large proportion of those
slums are situated in ﬂood-prone areas near the Atlantic coast-
lines.20 It is probable that the combination of climate change,
increased risk of ﬂooding, population growth, and urbanization
will lead to an increase in the burden of leptospirosis in Sub-
Saharan Africa.21
Diagnosis
Clinical and laboratory ﬁndings are non-speciﬁc, and a high
index of suspicion is required based on epidemiological exposure
associated with clinical signs and symptoms. Supplementary
Material Box 1 provides a concise overview of the diagnostic
methods; Supplementary Material Box 2 details the current case
deﬁnitions.5
Prevention and treatment
Vaccines tested in humans to date are of limited, if any, value
due to an unfavourable adverse events proﬁle, insufﬁcient
protection levels, and the variety in patterns of circulating
serovars.2 Serovar-speciﬁc vaccination is widely used in livestock
and dogs,2 but yields variable levels of protection, possibly
preventing illness but not leptospiruria,22–25 and therefore not
the transmission to humans. Doxycycline as a prophylactic could
not be proven effective in humans.13
Measures for preventing human leptospirosis include avoid-
ing possible sources of infection, antibiotic prophylaxis in those
at high risk, and possibly animal vaccination. Preventive
measures depend on the epidemiological pattern. In tropical
areas, where more serovars circulate, large numbers of mainte-
nance hosts exist and infection results from environmental
contamination, with peaks after rainy and harvest seasons, and
outbreaks potentially following ﬂoods or other natural disasters.Therefore, rodent and wet area control are important measures.
In urban environments, when infrastructure is disrupted or
underdeveloped, rodent control is also of use.
Severe leptospirosis should be treated with intravenous
penicillin immediately after the diagnosis is considered.26
Aggressive supportive care is essential and potentially life-
saving.27 In mild cases, oral treatment with doxycycline, azithro-
mycin, ampicillin, or amoxicillin is recommended. However, the
beneﬁt of antibiotic treatment for leptospirosis could neither be
proven nor refuted due to insufﬁcient evidence.12 Further clinical
research is needed.
2. Methods
The methods applied to prepare this systematic review are
described in detail in Supplementary Material Box 3. They were
speciﬁed in advance and documented in a protocol, including
objectives and inclusion criteria (Supplementary Material, File I:
Protocol).
3. Literature search results
The literature search ﬂow is depicted in Figure 1. Details of the
literature search results are provided in Supplementary Material
Box 4. An overview of the studies is given in Tables 1–4 and
Figures 2, 4 and 5.
Box 2. Case definitions for human leptospirosis (Adapted and
modified from WHO5/CDC)
A. Clinical description:
A common presentation is an acute febrile illness with head-
ache, myalgia (particularly calf muscle) and prostration asso-
ciated with any of the following symptoms/signs:
 Conjunctival suffusion
 Anuria or oliguria
 Jaundice
 Cough, haemoptysis and breathlessness
 Haemorrhages (from the intestines; lung bleeding is notori-
ous in some areas)
 Meningeal irritation
 Cardiac arrhythmia or failure
 Skin rash
 Aseptic meningitis*
Note. Other common symptoms include nausea, vomiting,
abdominal pain, diarrhoea and arthralgia. The clinical diagno-
sis is difficult where diseases with symptoms similar to those
of leptospirosis occur frequently. *Only mentioned in CDC
Case Definition of leptospirosis in 2013.
B. Laboratory criteria:
Laboratory-confirmed cases of leptospirosis: Clinical signs
and symptoms consistent with leptospirosis and any one of
the following:
 Fourfold increase in microscopic agglutination test (MAT)
titre in acute and convalescent serum samples;
 MAT titre 1:400 in single or paired serum samples;
 Isolation of pathogenic Leptospira species from normally
sterile site;
 Detection of Leptospira species in clinical samples by histo-
logical, histochemical or immunostaining technique;
 Pathogenic Leptospira species DNA detected by PCR
Probable cases of leptospirosis: Clinical signs and symptoms
consistent with leptospirosis and one of the following:
 Presence of IgM or a fourfold increase in indirect immuno-
fluorescence assay (IFA) antibody titre in acute and conva-
lescent serum samples;
 Presence of IgM antibodies by enzyme-linked immunosor-
bent assay (ELISA) or dipstick;
 MAT titre 1:100 in single acute-phase
Seroprevalence studies of healthy people, any of the follow-
ing:
 MAT titre  1:80
 Presence of IgM antibodies by ELISA or IFA
Seroprevalence studies of healthy animals, any of the follow-
ing:
 MAT titre  1:80
 Presence of IgM antibodies by ELISA or IFA
 Isolation of pathogenic Leptospira species from normally
sterile site;
 Detection of Leptospira species in clinical samples by histo-
logical, histochemical or immunostaining technique;
 Pathogenic Leptospira species DNA detected by PCR
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4.1. West Africa
Characterized by diverse climates, ranging from the Sahara
desert and semi-arid Sahel in the north to a belt of tropical forestson the southern coast, the region harbours numerous large,
overcrowded cities. These are often situated in more tropical
southern areas where heavy rainy seasons and slums with poor
sanitation are present. Data are available from seven of 16 West
African countries, with the majority of data from Nigeria (n = 18)28–
44 and Ghana (n = 7).45–51
In Nigeria, three background serosurveys in healthy people
yielded leptospiral antibody prevalences ranging from 13.5% in
Eastern State30 to 18.0% in Plateau State,31 and 20.4% in a
countrywide survey;29 signiﬁcantly higher prevalences were
found in coal mine workers,30 abattoir workers,30,31 and farm-
ers.29–31 A recent risk analysis among abattoir workers revealed
low levels of awareness and high levels of risk-of-exposure-prone
practices.52 No surveys on leptospirosis as a cause of febrile illness
have been conducted in Nigeria; however, a recent case report
from Plateau State proved it to be a diagnosis to consider in febrile,
icteric illness.53 Livestock has been studied extensively in
Nigeria.28–44 Leptospirosis affecting livestock can cause reproduc-
tive problems (e.g., abortion) and consequently huge economic
losses. Several surveys in cattle have been done in Zaria in the
central northern Kaduna State, displaying varying prevalences:
3.5% (5/142),40 6.8% (5/74),41 8.4% (20/237),38 and 11.0% (18/
164).40 Other studies have demonstrated leptospirosis in cows in
Plateau State42,43 and Ibadan,33 and in dogs,35,36 sheep, goats, and
pigs.34 Two rodent studies in Plateau State showed seropreva-
lences between 0.0% and 44.8%.41
In Ghana, only humans have been studied.45–51 Hogerzeil and
colleagues demonstrated a seroprevalence of 33.3% in 460 healthy
inhabitants from the Ashanti district, with a signiﬁcantly higher
prevalence in bush farmers and cocoa plantation workers.50
Concomitantly, they demonstrated conﬁrmed leptospirosis in 3.2%
of 190 patients with jaundice and/or undifferentiated fever in the
same region. In 1973, a 21.2% seroprevalence was demonstrated in
ill people from the Ashanti and Volta regions.51 This millennium,
four surveys were conducted in febrile patients; numbers varied
from 0.0%45 and 1.7%48 to 7.8%45 in the Accra region. In the
Northern Region, leptospirosis was diagnosed in one of
263 patients.47
Recent work from Cotonou, Benin, showed a prevalence of
18.9% in 90 rodents.54 Rodents from Conakry, Guinea, yielded
lower ﬁgures: 1.5% of 330 rodents were PCR-positive just after the
rainy season. The same study demonstrated leptospirosis in 3/172
individuals (1.7%) with an undifferentiated febrile disease (UFD).55
In Senegal32,56,57 and Cape Verde,58 four surveys were
performed in the 1970s and 1980s. In the Dakar region, 6.4% of
109 ill patients had positive titres, predominantly against the
Icterohaemorrhagiae serogroup.32 In a Dakar abattoir, with
animals from all over the country, seroprevalence in cattle was
20.8% and in sheep, goats, and pigs was 5.0%.57 On Santo Anta˜o and
Santiago, a serosurvey showed a prevalence of 7.2% in 611 healthy
inhabitants, and lower rates in cattle, donkeys, sheep, and goats.58–
60
No data were retrievable from other West African countries,
except for Mali. A Bamako survey showed 44.9% of 642 dairy cows
to be seropositive.61 No human data exist from Mali except for a
case report.62
4.2. Central Africa
Data from the Central African region are very limited. Even
though van Riel and colleagues performed extensive research on
the disease in the Democratic Republic of Congo from 1939 on-
wards (see Supplementary Material, File VII), no data were
published after the country’s independence in 1960. In 1995, a
survey was performed in the Katana Hospital in the Kivu region,
before the onset of a longstanding, violent conﬂict. In a prospective
Box 3. Methods
This systematic review was registered in advance in PROS-
PERO, an international database of prospectively registered
systematic reviews in health and social care (Registration
number: CRD42013006545).179We followed recommendations
made by the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) group.180 We searched the elec-
tronic databases MEDLINE/PubMed (1946 to January 2014),
Embase (via Ovid, 1947 to January 2014), The Cochrane Library
(January 2014), Web of Science (1975 to January 2014), Biosis
Previews (1993 to January 2014), The Cumulative Index to
Nursing and Allied Health Literature (CINAHL) (1937 to January
2014), the African Index Medicus (1993 to January 2014),
African Journals Online (AJOL) (January 2014), Google Schol-
ar (January 2014) for studies published up to 13 January
2014 without date, publication status or language restrictions.
The search strategy consisted of free-text words and subject
headings related to leptospirosis and countries in sub-Saharan
Africa according to the United Nations. The full search strate-
gies for every searched database are reported in supplemen-
tary file II: Search strategies. Data on leptospirosis in each
member country were requested from official national orga-
nizations. All primary trial registries that participate in the
WHO’s International Clinical Trial Registry were searched to
identify ongoing, terminated, or planned trials (see supple-
mentary file III: Trial registries). The archive at the KIT Biomedi-
cal Research in Amsterdam was searched for additional
papers. An experienced clinical librarian (IMN) conducted
the actual searches on 24 to 26 October 2013 and an update
search on 13 January 2014. Bibliographies of relevant studies
retrieved from the studies were checked for additional pub-
lications. We used Reference Manager 12.0.3 (Thomson Reu-
ters) to manage, de-duplicate, and screen the references for
eligibility.
Selection criteria for inclusion of retrieved studies were as
follows: the study population consisted of any group of people
or mammals in sub-Saharan Africa who had been tested for
leptospirosis or leptospiral antibodies, of all age groups. De-
scriptive, cross-sectional studies, prospective, or retrospective
studies and case reports and series in which the prevalence rate
of leptospirosis in any country in sub-Saharan Africa was
reported were included. Conference abstracts were also includ-
ed. Only studies published after 1970 were included in the
present systematic review. An overview of the historic articles
published before 1970 is given in additional file 5: Historic
leptospirosis. Studies performed on the Western Indian Ocean
islands and Madagascar were excluded because an extensive
systematic review was published recently on this topic.181
Eligibility assessment of studies found was performed inde-
pendently in an unblinded standardized manner by 2 authors
(SGV & BJV). Titles and abstracts were screened first; next,
SGV screened and selected relevant full-text articles. Disagree-
ment in the selection process between reviewers were re-
solved by consensus or on consultation with the senior
review author (MPG). We summarized the study selection
process in the PRISMA flow diagram (Figure 1). Risk-of-bias
assessments were performed independently by two review
authors (SGV & BJV) for all included human studies, using an
unique assessment tool, extracted and modified from an evi-
dence based tool182 (see supplementary file VIII). The tool was
pilot-tested on five randomly selected studies by both
reviewers. No studies were excluded on the basis of quality.
We developed a data extraction sheet (modified version of the
Cochrane Consumers and Communication Review Group’s data
extraction template), pilot-tested it and refined it accordingly.
SGV extracted the following study characteristics: first author,
year of publication, PubMed ID if available, language, study
site & setting, study design, characteristics of trial participants,
objectives / measure of primary outcome, target population and
selection criteria, total enrolment, attrition rate (if applicable),
sample size, diagnostic methods and cut-off values and, if
applicable, prevalence of leptospiral antibodies, leptospiral
serovars/serogroups/strains, characteristics of leptospirosis
cases, risk factors, seasonal influences, demographics, co-
infections, treatment, and mortality. Leptospiral serovars and
strains were placed in serogroups according to the ‘‘Leptos-
pira Library’’ from KIT Biomedical Research.183 95% confi-
dence intervals (CI) of prevalence rates were calculated using
the modified Wald method. The following equations were
used. p’= (S+0.5z2)/(n+z2) (S= numerator, n= denominator, z=
1.96, as for a 95% confidence interval) and concomitantly to
compute the margin of error of the CI: W= z H((p’(1-p’))/(n+z2)).
Data was plotted in forest plots using Prism version 6.0
(GraphPad Software, Inc., CA, USA). The primary outcome
in the present review is the prevalence of leptospirosis in
countries in sub-Saharan Africa. Secondary outcomes in-
clude risk factors, circulating serogroups, serovars and/or
strains, clinical manifestations, treatment, prevention mea-
sures, seasonal influences, and mortality. Extracted data was
double checked by BJV for all the included articles (n=140)
using the original records. Regional and national WHO offices
were contacted for additional data on leptospirosis in the
region, but this did not result in additional data. We did not
contact authors for further information or confirm the accu-
racy of information included in our review with the original
researchers, since for the majority of papers adequate contact
information was missing. A meta-analysis could not be per-
formed due to the clinical heterogeneity, and the non-unifor-
mity of the diagnostic tools and case definitions. We did not
investigate publication bias.
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of acute leptospirosis was established in one of 65 patients. This is
probably an underestimation since the study was not designed to
detect leptospirosis. Subsequently, a serosurvey in 61 antelopes
from the Ituri Rainforest showed leptospiral antibodies in 26.2%.64
Most Central African data come from Gabon where in the
1990s, two surveys were performed in people.65,66 A seropreva-
lence of 15.7% in healthy people was demonstrated in ﬁve villages
in the northeast.65 No risk factors could be determined; members
from the Bakoule tribe, traditionally ﬁshermen, were found to
have a higher risk of being seropositive. All villages were located in
a gold panning area; however this activity was not found to
constitute a risk factor. Of 52 French military personnel
presenting with UFD in Libreville, two had high single antibody
titres against pathogenic serovars.66 They had been dispatched in
the ﬁeld and exposed to fresh water. Recently, a case series was
published of four men from poorer areas in Libreville with proven
acute leptospirosis.67
Scolamacchia and colleagues68 designed a prevalence model for
cattle from the Adamawa region in Cameroon, adjusting for the
diagnostic test performance and study design. Based on banked
sera of 1377 cows from 146 herds, they estimated the region-wide
animal prevalence to be 30.4%, and 93.0% of herds to be positive.
The only other report originating from this region is a case
report of a military dog from Chad with leptospirosis-induced renal
insufﬁciency.69
4.3. East Africa
Most epidemiological data on leptospirosis in East Africa
originate from Kenya70–86 and Tanzania.9,87–89 Since the 1950s,
Kenya has been key in establishing knowledge on the epidemiolo-
gy of leptospirosis on the African continent. Since 1997, Tanzania
has evolved as the focus of many leptospirosis studies.
The only well established incidence calculation for leptospirosis
in Sub-Saharan Africa was done in 2013, for the rural and urban
Box 4. Literature search results
The initial search yielded 910 records, of which 398 remained
after the removal of duplicates (see PRISMA flow diagram,
Figure 1). Another additional 31 references from bibliogra-
phies of screened studies were identified and screened. Of
the 429 screened records, 140 records met the inclusion criteria
for this review. Of the excluded studies, 40 were published
before 1970 and are not discussed in the present review; an
overview of these historic records can be found in Supplemen-
tary file VII.
Of the 140 included studies, four were conference abstracts of
studies never published and five studies were mentioned in
theses or other articles, but never published in an online
database. The majority of records were published in English:
eight were published in another language (French, n = 6;
German, n = 1; South African, n = 1). For a general overview
of characteristics of included studies, see Table 1. Studies were
found from 27 of 44 sub-Saharan African countries. Overall
quality assessment scores for risk of bias in studies included in
the review ranged from three to ten, out of a maximum of ten.
Of the total 35 studies assessed, 23 were scored >7, of which
15 were scored >8. All studies were observational studies.
Table 2 and 3 provide overviews of surveys of human and
animal leptospirosis reported from sub-Saharan Africa. There
were no outbreak reports in animals. Table 4 details a miscel-
laneous study. Supplementary files IV and V provide detailed
information about individual case reports and case series of
leptospirosis in people in sub-Saharan Africa and surveys of
leptospirosis in humans and animals from this region; supple-
mentary file VI an overview of circulating serogroups and an
overview of research published before 1970 can be found in
supplementary file VII.
Figure 1. PRISMA ﬂow diagram of study selection.
S.G. de Vries et al. / International Journal of Infectious Diseases 28 (2014) 47–64 51area of Moshi, in the Kilimanjaro Region of Tanzania.87 Based on a
prospective cohort study,9 the overall estimated incidence was
75–102 per 100 000 persons per year, with the highest incidence
in children under 5, i.e., 175–288 cases per 100 000 per year
(Table 2). This is probably an underestimation because it only
represents hospitalized cases. The higher incidence in younger
children can be explained by their lower admission threshold.87 In
the aforementioned study among febrile adults and children,9
8.4% (70/831) of serologically tested participants met the
deﬁnition of conﬁrmed or (highly) probable leptospirosis;
another 277 patients (364%) exhibited evidence of exposure.
Patients with conﬁrmed or probable leptospirosis were older than
those without (p < 0.001), and serological evidence of exposure
increased with age (p < 0.001). In adults, thrombocytopenia was
associated with conﬁrmed (OR 3.5, p = 0.005) and probable disease
(OR 2.2, p = 0.017). In children, lymphadenopathy was associated
with leptospirosis (25.9% vs. 9.2%; p = 0.14). The study
demonstrates the lack of clinician awareness of leptospirosis:
provisional diagnoses in conﬁrmed and probable cases were
mainly malaria and pneumonia; leptospirosis was never included
into the differential diagnosis. Of conﬁrmed cases, 40% suffered
from a co-infection; HIV (15%), rickettsiosis, brucellosis, and
community-acquired blood stream infections (12.5% each) were
most prevalent. No association between HIV and leptospirosis
could be demonstrated, in contrast to the later re-analysis of thisTable 1
Overview of the studies included
Human surveys Human and animal surveys 
West Africa 12 3 
Central Africa 3 0 
East Africa 12 2 
Southern Africa 2 4 
Travellers 3 0 
Total 32 9 
Percentage 22.9% 6.4% study,9 where leptospirosis was found to be less prevalent in a
group of HIV-infected patients (OR 0.43, p = 0.019).90 The only risk
factor identiﬁed was living in a rural area (OR 3.4, p < 0.001). No
characteristic link was found between chest X-ray abnormalities
and leptospirosis.91
In the Tanga region, bordered by the Indian Ocean and
Kilimanjaro mountains, a 2009 survey showed a seroprevalence
of 15.1% among 199 healthy inhabitants; milking of cows
constituted a risk (OR 3.44, p < 0.001).88 Serosurveys in cattle
demonstrated prevalences varying from 11.0%92 and 30.0%93 in
larger surveys to up to 51.0% in a smaller abattoir survey.94 A
countrywide serosurvey among healthy blood donors (n = 375)
yielded a low prevalence of 0.3%;89 however, the sera were only
screened against three serovars.
First reports of leptospirosis in Kenya date from 1944 in cattle.
De Geus and colleagues later conducted two studies in Coast76 and
Nyanza provinces,75 in adults and children with UFD or jaundice.
Applying strict case deﬁnitions, 11.0% from 91 patients from Coast
province and 3.2% of 281 patients from Nyanza province wereCase reports Animal Total Percentage
3 15 33 23.6%
4 4 11 7.9%
1 30 45 32.1%
5 34 45 32.1%
3 0 6 4.3%
16 83 140 100.0%
11.4% 59.3% 100.0%
Figure 2. Availability and nature of reported epidemiological data. Prevalences and
numbers refer to human cases unless speciﬁed otherwise.
S.G. de Vries et al. / International Journal of Infectious Diseases 28 (2014) 47–6452found to suffer from acute leptospirosis. A signiﬁcantly higher
prevalence in males and in hospitals close to sugar estates was
found.95,96 In 1987, 7.4% of 353 healthy people in Nyanza province
and 16.9% of 130 in Coast province were found to have leptospiral
antibodies.74 A recent outbreak investigation of malaria-negative
fever in 21 patients in Malindi in Coast province could not conﬁrm
leptospirosis.70
In Kibera, a densely populated part of Nairobi with poor
sanitary conditions, leptospiral DNA was recently demonstrated
in 41/224 (18.3%) rodents.77 Human data available from Nairobi
are from 1987; 207 healthy subjects did not yield any leptospiral
antibodies.74 Recent studies in patients with UFD in North East
province did not show any positive Leptospira PCRs;71 however,
no serological tests were performed, yet a case series after an
outbreak of acute febrile illness amongst pastoralists showed
leptospiral antibodies in 3/12 patients.72 In the 1980s, a
seroprevalence study was performed amongst people from
Nyandarua (0.0%) and Turkana (4.6%) districts; it showed high
seroprevalences in Nyandarua sheep, goats, and cattle (34%
each). Lower prevalences were reported in Turkana.73 A
1982 countrywide study in 2864 cows showed a seroprevalence
of 25.0%.81 Ten years later, 898 sheep and goats from all over the
country were found to have an antibody seroprevalence of
16.0%.79
In Ethiopia, three serosurveys97–100 performed in several
animal species in the 1970s demonstrated leptospirosis endemici-
ty.99,100 In 2004, 47.5% of 59 febrile patients in Wonji tested
positive for leptospiral antibodies with the LeptoTek Dri-Dot test.97
However, these results could not be reproduced or conﬁrmed in a
reference laboratory (Royal Tropical Institute, the Netherlands)
(MGAG, personal communication).
In Somalia, from 1975 to 1976,101 37.1% of 105 healthy adults
from (dry) Mogadishu were found to be seropositive, with a
signiﬁcantly higher seropositivity in people from wetter areas near
the Shabeele River (63.5%; 68/107); close contact with cattle was a
risk factor.Data from other East African countries are scarce. Recently,
leptospirosis was demonstrated in Uganda; 26.7% of 116
owned dogs from in and around three national parks were
seropositive.102 An earlier study in buffalos from the same park
showed no signs of leptospirosis.103 A study in Djibouti104
revealed a remarkably high seroprevalence in small groups
of horses, camels, and cattle. Figures from Sudan date back
to the 1980s, when 15.3% of 1142 cows105 from all over the
country were seropositive (9.8% of a group of 717 wild mammals
from Melut district);60 infection was also demonstrated in
rodents.105
4.4. Southern Africa
Forty-six studies from Southern Africa were identiﬁed (see
Table 1). Most studies came from South Africa (n = 15)80,106–120 and
Zimbabwe (n = 17).121–136 No data were found from Swaziland and
Lesotho.
Feresu and colleagues established knowledge on leptospirosis
in Zimbabwe in 1995/6. They demonstrated that 83.5% of
182 workers and their families from two farms in and around
Harare carried leptospiral antibodies in one of the samples after
following them up for 1.5 years; seasonal inﬂuences were not
identiﬁed.121 Of 437 rodents from the same farms, 62.5% were
seropositive.121 In the early 1980s, 26.8% of a cattle herd (n = 2382)
were seropositive,127 and leptospires were later isolated in 10.4%
of 480 cattle in a Harare abattoir.129 These isolates revealed
several new serovars and strains.130–134,136 In Harare, rural dogs
(n = 250) were found to have a positive ELISA in 15.6%.122 Similar
numbers in dogs were found in 1979.137 Zimbabwean wildlife has
been studied. In rhinoceroses, numbers varied from 63.0% (38/
60)125 to 4.9% in a group of 102.124 Buffalos, elands, wildebeests,
and zebras were also found to carry antibodies.124 No other
human data from Zimbabwe were retrieved except two case
reports.138,139
Human data from South Africa are relatively scarce; two
surveys have been published.107,140 In 2010, 7.8% of 332 febrile
patients from Johannesburg were seropositive.140 A survey in
Durban among healthy volunteers showed a seroprevalence of
18.9%, with a signiﬁcantly higher percentage among youth aged
18–22 years.107 The latter study found seropositivity in 22 of
221 rodents trapped in the same area, and 14.5% of 69 kidneys to be
PCR-positive. Other sporadic data on human leptospirosis date
from the 1980s.141–143
Concerning livestock, a survey in 33 districts of KwaZulu-Natal
proved 19.4% of 2021 cows to be seropositive.109 Other surveys
showed numbers varying from 3.0% (of 860 cows) in Mpumalanga
province114 to 52.4% in Transvaal.116 Cows and pigs showed high
prevalence rates after abortion on farms in Mpumalanga, Gauteng
province, and Free State.110 Earlier outbreak investigations
amongst pigs showed similarly high rates.120 An abattoir
serosurvey demonstrated a 22.2% prevalence in 5041 pigs from
several regions.111 In Transvaal, 1.3% of 152 sheep had anti-
bodies.116
Seropositivity was demonstrated in rhinoceroses (n = 182)
from four national parks (26.4%),80 buffaloes from Kruger
National Park (7/406),114 in a small group of wild animals from
Northern Natal (12%),115 and in 1978 in 8.0% of 50 vervet
monkeys.119
In South African dogs, rates were equally varied: 86.5% in 37 ill
dogs in the early 1970s120 and 1.5% (6/400) in healthy dogs in
Pretoria;112 a recent study in four coastal regions demonstrated a
seroprevalence of 4.7% in 530 dogs. Stray dogs were 4.4 times more
likely to have antibodies compared to owned dogs (7.6% vs. 1.9%, p
= 0.0017), with dogs in KwaZulu-Natal and Eastern Cape more
likely to be positive.108
Figure 3. Malawian cattle, typical probable host for leptospirosis.
S.G. de Vries et al. / International Journal of Infectious Diseases 28 (2014) 47–64 53In Angola, in a group of 650 febrile patients, 8.0% were probable
cases of leptospirosis. Thirteen percent of 77 rodents showed
PCR-positive kidney samples.144 Zambian rodents recently showed
a low seroprevalence (1/466).145 Of note, reservoir rodents often
do not have antibodies against the serovar they are carrying.146 A
survey of piggeries around Lusaka showed positive serology in
15% of 121 pigs.126 No data for human infection are available from
Zambia, Malawi, or Botswana. The only available countrywide
Malawian survey showed a 21.5% (59/275) seroprevalence in
cattle in 1989.147 Recently, 43.0% of 42 Botswanan mongooses
had PCR-positive kidney tissue.148 After a 1983 abortion cluster
in cattle in Chobe district (Botswana), 27/40 cows were
seropositive.149
In Mozambique, 8.8% of 160 febrile patients in Maputo carried
leptospiral antibodies. In a subgroup of 43 patients with a non-
speciﬁc febrile illness, four (9.3%) showed high microscopic
agglutination test (MAT) titres, which could direct towards acute
leptospirosis. No risk factors were identiﬁed.150
4.5. Travellers ex Africa
Leptospirosis is sporadically reported in travellers from Africa.
The GeoSentinel Surveillance Network reported ﬁve cases of
leptospirosis in travellers coming from Sub-Saharan Africa
between 1996 and 2011.152 EuroTravNet reported one case each
from Cameroon, the Central African Republic, and Re´union.153
Returning from a water sports holiday in South Africa, a 49-year-
old man presented with acute leptospirosis and a Jarisch–
Herxheimer reaction after treatment initiation. He recovered
completely.154 A young Australian female returning from Nigeria
died due to myocarditis and a complete AV block due to
haemorrhages caused by Leptospira icterohaemorrhagiae.155 A
French female returning from Ivory Coast was reported ill in
1997, having lived in a rural area with extensive livestock
contact.156 In the Netherlands alone, seven travellers returning
from Sub-Saharan Africa were diagnosed with leptospirosis during
the period 1985–2008.6
5. Discussion
Leptospirosis is a zoonosis of global importance that remains
under-recognized in some parts of the world. This applies to
much of Sub-Saharan Africa, reﬂected in the fact that only
observational studies were identiﬁed, while interventional
studies are lacking. With an ever-growing proportion of febrile
disease episodes being recognized as non-malarial (due to the
recent scaling-up of rapid diagnostic malaria testing before
treatment initiation), leptospirosis is highlighted as one impor-
tant differential diagnosis. Additionally, adequate diagnostic
facilities across Africa are increasing. We depict leptospirosis as a
highly prevalent, ubiquitous disease in Sub-Saharan Africa and
conﬁrm the leptospirosis aphorism, ‘Wherever leptospires and
leptospirosis is searched for, they are invariably discovered’.157
However, our data compilation is not conclusive, due to
substantial between-study variability. Large regional differences
in reporting exist, and recent epidemiological data on the
prevalence of leptospirosis are scarce for many African countries,
particularly Central Africa. The paucity of efﬁcient surveillance
systems and data collection methods result in incomplete
information regarding disease epidemiology. Remarkably, more
research is conducted in animals compared to humans. This is
probably due to the larger economic losses caused by leptospi-
rosis in livestock (e.g. abortion) compared to losses due to human
morbidity and mortality. Undoubtedly, animal leptospirosis is
higher on the political agenda compared to its neglected human
counterpart.Epidemiological data derived from animal studies as de-
scribed in this review should be interpreted with caution. First,
the slaughter of animals above certain ages creates an unavoid-
able selection bias in (often abattoir-based) livestock surveys.
This gives a distorted prevalence picture because higher
leptospirosis seroprevalence is related to older host age. Second,
the prevalence and incidence of leptospirosis ﬂuctuates; there is
commonly more leptospirosis during and just after the rainy and
harvest season. Often, studies did not report season and the time
frame of the study period and they are therefore not easily
comparable. Finally, large proportions of reservoir hosts have no
antibodies against the serovar they carry (Figure 3). Thus, while
seroprevalence studies in healthy animal populations indicate
levels of local infection exposure, these are less suited to deﬁne
their role as infection reservoirs. Therefore, assumptions that the
seroprevalence in animals corresponds with leptospirosis preva-
lence or incidence in humans cannot easily be made. Animals
with low seroprevalence may be a substantial cause of infection
in humans; high seroprevalence may indicate exposure pressure
from different animal populations, hence a high infection risk in
humans as well.
In human studies, two types of survey are distinguished;
studies establishing leptospirosis prevalence as a cause of
(mostly febrile) illness and background seroprevalence studies.
The background studies showed variable, but generally high
seroprevalences, which were elevated in risk groups. This does
not necessarily mean a high disease burden; asymptomatic
seroconversion in young children in rural areas occurs,15 which
may apply to most leptospiral infections in general. Patient
surveys show varying data. An equivalent exposure level to
leptospirosis does not necessarily result in the same prevalence
of clinical disease, possibly due to different immunity patterns
and circulating serovars. Variations in inclusion criteria, case
deﬁnitions, and diagnostic tools make outcome data comparison
between different studies and regions challenging. In some of
the original articles, the terms fever of unknown origin (FUO) or
pyrexia of unknown origin (PUO) have been used. With some
degree of uncertainty as to whether these classiﬁcations would
match with the precise deﬁnition of what constitutes FUO
Figure 4. Prevalence of leptospirosis in studies on diseased subjects, presented with their 95% conﬁdence intervals.
Figure 5. Prevalence of leptospirosis in studies on healthy subjects, presented with their 95% conﬁdence intervals.
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Table 2
Leptospirosis in humans in Sub-Saharan Africa published after 1970
Country Region and Ref. Method Number of
individuals
Prevalence/incidence Quality (1–10)
West Africa
Cape Verde Islands Santo Anta˜o and Santiago58 Cross-sectional serosurvey healthy people; MAT (12 serovars), positive
1:100
611 7.2% (95% CI 5.7–9.1%) 8
Ghanaa Accra46 Cross-sectional study in patients with UFD; IgM ELISA 166 7.8% (95% CI 4.5–13.0%) 8
Ghanaa Accra + northern region45 Cross-sectional study in patients with UFD; IgM ELISA and PCR 180 ELISA
40 PCR
7.8% (95% CI 4.6–12.7%) (ELISA)
0.0% (95% CI 0.0–7.6%) (PCR)
7
Ghana Northern region47 Cross-sectional survey; inclusion criteria NR; method NR 263 0.4% (95% CI 0.0–2.3%) 3
Ghanaa Greater Accra region48 Cross-sectional study in patients with FUO ‘‘Serology with 4 titre rise’’ 172 1.7% (95% CI 0.4–5.2%) 6
Ghana Ashanti-Akim district50 Cross-sectional serosurvey of healthy people; MAT (24 serogroups),
positive 1:20
460 33.0% (95% CI 28.9–37.4%) 7
Ghanaa Ashanti-Akim district49 Prospective cohort study
Group A: UFD + jaundice with a high degree of suspicion of acute LS
Group B: Any patient presenting with jaundice
MAT (23 serogroups), 4 titre rise
Group A: 88
Group B: 102
4.5% (95% CI 1.4–11.4%) (Group
A)
2.0% (95% CI 0.1–7.3%) (Group
B)
10
Ghanaa Ashanti region + Volta region51 Cross-sectional study in suspected cases of LS and jaundice; MAT
(16 serogroups), positive 1:300
99 21.2% (95% CI 14.2–30.3%) 5
Guinea Conakry55 Cross-sectional survey healthy people
ELISA IgM + IgG, MAT
1200 7.0% (95% CI 5.7–8.6%) 6
Nigeriaa Abuja28 Case–control study in kennel workers after LS outbreak dogs: ELISA 10 cases
10 controls
100.0% (cases)
0.0% (controls)
7
Nigeria Countrywide29 Cross-sectional serosurvey of healthy people; MAT (12 serovars),
positive 1:100
538 20.5% (95% CI 17.3–24.1%) 9
Nigeria Enugu + other eastern states30 Cross-sectional serosurvey of healthy people; MAT (11 serovars),
positive 1:100
661 13.5% (95% CI 11.1–16.3%) 8
Nigeria Plateau State31 Cross-sectional serosurvey of healthy people
MAT (13 serovars), positive 1:100
710 18.0% (95% CI 15.4–21.0%) 8
Senegala Dakar32 Cross-sectional study in patients with suspicion of LS; MAT
(16 serogroups), positive 1:100
109 6.4% (95% CI 2.9–12.9%) 8
Central Africa
DRC (Zaire)a Kivu Mountains63 Prospective cohort study in patients with haemoglobinuria; IgM ELISA,
4 titre rise
38 5.3% (95% CI 0.5–18.2%) 8
Gabon Northeast65 Cross-sectional serosurvey of healthy people; MaAT 235 15.7% (95% CI 11.6–21.0%) 6
Gabona Libreville66 Cross-sectional study in military Frenchmen with UFD (Temp. 39 8C,
nomalarial parasites, no other explanation). ScreeningwithMaAT, then
IgM ELISA, then MAT (19 serovars), positive 1:100
55 5.5% (95% CI 1.3–15.4%) 6
East Africa
Ethiopiaa Wonji97 Cross-sectional ﬁeld study, malaria-negative febrile patients; LeptoTek
Dri-Dot
59 47.5% (95% CI 35.4–60.0%) 5
Kenyaa Malindi, Coast Province70 Outbreak investigation of malaria-negative acute fever; PCR + ELISA 21 0.0% (95% CI 0.0–13.5%) 5
Kenyaa North Eastern Province71 Cross-sectional survey among patients with non-malarial fever; RT-
qPCR
304 0.0% (95% CI 0.0–1.1%) 8
Kenyaa Damajale, North Eastern Province72 Retrospective outbreak investigation, patients with new-onset fever/
arthralgia; IgM ELISA
12 25.0% (95% CI 8.3–53.9%) 6
Kenya Nyandarua + Turkana districts73 Cross-sectional serosurvey of healthy people; MAT (11 serovars),
suspicious 1:50; positive 1:200
681
Nyandaru 315
Turkana 366
Nyandaru: 0.0% (95% CI 0.0–
1.5%) positive; 7.6% suspicious
Turkana: 4.6% (95% CI 2.9–7.4%)
positive; 9.3% suspicious
8
Kenya Nairobi, Miwani + Ramisi74 Cross-sectional serosurvey of healthy people; IgM ELISA +MAT, positive
1:80
690 7.0% (95% CI 5.3–9.1%)
(Miwani 7.4%, Ramisi 16.9%,
Nairobi 0.0%)
8
Kenyaa Coast Province76 Prospective cohort study, patients with UFD/ jaundice; MAT, positive
>1:3000 or 10 titre rise in convalescent sera
91 11.0% (95% CI 5.9–19.2%) 8
Kenyaa Nyanza province75 Prospective cohort study, patients UFD/jaundice; MAT, positive
>1:3000 or 10 titre rise in convalescent sera
281 3.2% (95% CI 1.6–6.1%) 8
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Table 2 (Continued )
Country Region and Ref. Method Number of
individuals
Prevalence/incidence Quality (1–10)
Tanzaniaa Moshi87 Incidence calculation Based on Biggs et al., 20119 Incidence:
Overall estimated 75–102 per
100 000 persons
0–<5 years: 175–288 cases
5–<15 years: 149–161 cases
15 years: 33–59 cases
9
Tanzaniaa Moshi9 Prospective cohort study of febrile patients;
MAT (17 serogroups), conﬁrmed 4 titre rise: probable 1:800,
exposure 1:100
831 total sera
453 paired sera
8.4% (95% CI 6.7–10.5%)
conﬁrmed/probable
36.4% (95% CI 33.1–40.0%)
evidence of exposure
9
Tanzaniaa Tanga City88 Cross-sectional serosurvey of healthy people; MAT (6 serovars),
positive 1:160
199 15.1% (95% CI 10.7–20.8%) 7
Tanzaniaa Countrywide89 Cross-sectional serosurvey of healthy people; MAT (3 serovars),
positive 1:160
375 0.3% (95% CI0.0–1.7%) 5
Somalia Mogadishu area + Shabeele River101 Cross-sectional serosurvey in healthy people and in patients with
suspected viral hepatitis; MAT (20 serovars), positive 1:100
372 33.6% (95% CI 29.0–38.6%)
(Mogadishu 37.0%, Shabeele
64.0%, ill Mogadishu patients
56.2%)
8
Southern Africa
Angolaa Huanda + Luambo144 Cross-sectional survey in febrile patients; MAT, positive 1:100 650 8.0% (95% CI 6.1–10.4%) 7
Mozambiquea Maputo150 Cross-sectional study in febrile patients; MAT (20 serovars), positive
1:100
160 8.8% (95% CI 5.2–14.3%) 8
Namibia Kavango160 Cross-sectional study, healthy adults + patients with immune
thrombocytopenic purpura; MAT (case deﬁnition NR)
211 2.8% (95% CI 1.2–6.2%) 6
South Africaa Johannesburg106 Cross-sectional survey in febrile patients; IgM ELISA+ nested PCR 332 ELISA
247 PCR
7.8% (95% CI 5.4–11.3%) (ELISA)
0.0% (95% CI 0.0–1.3%) (PCR)
7
South Africa Durban107 Cross-sectional serosurvey in healthy people: MAT (case deﬁnition NR) 217 18.9% (95% CI 14.2–24.7%) 7
Zimbabwe Harare, two farms121 Cross-sectional survey of healthy farm workers and families; MAT
(8 serogroups), positive 1:100
182 83.5% (95% CI 77.4–88.3%) 7
CI, conﬁdence interval; MAT, microscopic agglutination test; UFD, undifferentiated febrile disease; NR, not reported; FUO, fever of unknown origin; LS, leptospirosis; MaAT, macroscopic agglutination test.
a Studies performed on diseased subjects.
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S.G. de Vries et al. / International Journal of Infectious Diseases 28 (2014) 47–64 57according to the current accepted deﬁnition, we decided to refer
to those conditions consistently as ‘undifferentiated febrile
disease’ (UFD) in order to avoid confusion.
Further studies are required to elucidate the exact epidemiol-
ogy of leptospirosis in Sub-Saharan Africa. Even in regions where
leptospirosis research has been conducted, such as East Africa,
researchers believe that it remains under-diagnosed because of
lack of awareness, facilities, and surveillance systems. Many
questions remain unanswered, and new questions continue to
arise (see Panel following the Conclusions). Moreover, countries
are confronted with larger scale epidemics (HIV, tuberculosis,
malaria), which consume already limited resources. Thus,
leptospirosis can be considered a neglected tropical disease in
Sub-Saharan Africa. Knowledge of the human leptospirosis
burden has not yet translated into increased or strengthened
control and prevention programmes, nor is it regularly considered
routinely as an important differential diagnosis in non-malarial
fevers.
In most countries, an adult predominance in clinical disease has
been noted, which is not reﬂected across all clinical surveys. The
only incidence calculation, from Tanzania, showed a higher
(serological) incidence in younger age groups,87 which can only
partly be explained by a lower hospital admission threshold for
children. Immunological and genetic host factors may play a
particular role in the development of active disease. However, the
same study showed that patients with conﬁrmed or probable
leptospirosis were older than those without leptospirosis;9 or
there was no difference in age groups at all.158 Almost certainly,
exposure to leptospirosis starts at a young age and infection often
remains unnoticed or undiagnosed.
The ﬁndings of this review are subject to methodological
limitations. Heterogeneity between studies was high. Few studies
reported sufﬁcient outcome data to allow for population compar-
isons. Novel diagnostic tests have shed more light on the
prevalence of leptospirosis and require further investigation.
Although we assessed the quality of included studies, we were
unable to control for differences in study design and quality of
microbiological data. For many surveys, the prevalence of
leptospirosis was not the primary outcome, making a formal
meta-analysis potentially misleading. Unpublished data were
included in this review (conference abstracts), although contro-
versy on this policy exists.159 We minimized bias by searching
clinical trial registries for ongoing or unpublished studies. Whilst
no restrictions were placed on the publication language, English
predominates, with Medline/PubMed being the primary source of
studies. Other unpublished data were not included; therefore, our
ﬁndings may have a publication bias towards studies that report
high levels of concordance.
6. Conclusions
Leptospirosis is an important zoonosis in Sub-Saharan Africa.
The combination of climate change, massive urbanization, and the
interdependence of humans and animals may be critical for the
burden of leptospirosis on Africa’s people. The nature of
leptospirosis highlights the need for a fresh approach to control
and prevention, incorporating the links between veterinary and
human medicine. Future leptospirosis research should be a
collaborative effort between the ﬁelds of human and animal
medicine to provide optimal health outcomes.
Panel: Present knowledge, unanswered questions, and research
gaps:Leptospirosis is common in Sub-Saharan Africa, as shown by
numerous observational studies
Which populations are most at risk? To what extent are lepto-
spirosis cases misclassiﬁed as malaria? Do more infections occur
in poorly sanitized urban settings or in rural areas as a result of
occupational or environmental exposure? How prevalent is the
disease in the Central African region?
The increasing urbanization and climate change are thought to be
risk factors for future outbreaks of leptospirosis in Sub-Saharan
Africa
What public health or control measures should be taken? Will
livestock vaccination, sanitation measures, and rodent control
be enough to prevent larger outbreaks?
Data on the risk of acquiring leptospirosis related to age vary and
remain unclear
Which age groups are most at risk? Is disease vastly under-
recognized in children due to their milder symptoms? What is
the inﬂuence of acquired immunity?
Antibiotic treatment is recommended but there are no clear-cut
clinical trials to prove or refute the use of antibiotic treatment for
leptospirosis
An almost certain cause of some of the inconclusive studies is
that patients in resource-poor countries arrive for treatment
with advanced disease. Antibiotics are then unlikely to be of
beneﬁt because organ damage has already occurred. How can
this problem be avoided in future clinical trials?
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Table 3
Leptospirosis in animals in Sub-Saharan Africa published after 1970
Country Region and Ref. Type of
animal
Method Number of
animals
Prevalence
West Africa
Benin Cotonou54 Rodents Organ survey, PCR kidney samples 90 18.9%
Cape Verde
Islands
Santo Anta˜o and Santiago58 Cattle Serosurvey (MAT 1:100) 150 2.0%
Cape Verde
Islands
Santo Anta˜o and Santiago58 Goats Serosurvey (MAT 1:100) 640 5.3%
Cape Verde
Islands
Santo Anta˜o and Santiago58 Sheep Serosurvey (MAT 1:100) 39 0.0%
Cape Verde
Islands
Santo Anta˜o and Santiago58 Donkeys Serosurvey (MAT 1:100) 61 3.3%
Cape Verde
Islands
Santo Anta˜o and Santiago58 Pigs Serosurvey (MAT 1:100) 316 0.0%
Cape Verde
Islands
Santo Anta˜o and Santiago58 Dogs Serosurvey (MAT 1:100) 89 0.0%
Cape Verde
Islands
Santo Anta˜o and Santiago58 Rodents Serosurvey (MAT 1:100) 211 0.0%
Cape Verde
Islands
Santo Anta˜o and Santiago58 Horses Serosurvey (MAT 1:100) 3 0.0%
Guinea Conakry55 Rodents Organ survey (PCR + culture of kidney
tissue)
330 1.5%
Nigeria Ibadan and Abeokuta33 Cattle Abattoir survey (kidney culture) 108 82.4% (Ibadan 95.2%; Abeokuta 79.3%)
Nigeria Ibadan34 Sheep Abattoir serosurvey (MAT 1:100) 255 23.5%
Nigeria Ibadan34 Goats Abattoir serosurvey (MAT 1:100) 320 13.1%
Nigeria Ibadan, Lagos and Ilorin35 Dogs Prospective serological survey in sick
dogs with positive LS serology
MAT positive 1:100 (vaccine serovars)
+ 4 rise in 10–14 days or single titre
1:800–1:3200 (non-vaccine serovars)
Vaccine serovars: Canicola and
Icterohaemorrhagiae
Treatment: ampicillin/amoxicillin/
enroﬂoxacin, rehydration, diuretics
52 (98% (51/52)
were primarily
vaccinated)
100.0% (see inclusion criteria)
Clinical signs: sudden illness, anorexia,
vomiting, depression, dehydration,
oliguria, subnormal rectal temp.,
anuria, renomegaly, uremia
Urinalysis: occult blood (61.5%),
bilirubin (51.9%), protein (11.5%)
Nigeria Ibadan36 Dogs Serosurvey (MAT) NR 16.7%
Nigeria Ibadan36 Pigs Abattoir serosurvey (MAT) 423 NR
Nigeria Kaduna State, Zaria40 Cattle Serosurvey (ELISA) 164 11.0%
Nigeria Kaduna State, Zaria38 Cattle Serosurvey (ELISA) 237 8.4%
Nigeria Kaduna State, Zaria39 Cattle Abattoir serosurvey (ELISA) 142 3.5%
Nigeria Kaduna State, Zaria41 Cattle Organ survey (culture) 74 6.8%
Nigeria Kaduna State, Zaria41 Rodents Serosurvey (NR) 252 4.0%
Nigeria Plateau State42 Cattle Serosurvey (MAT 1:100) 1537 14.4%
Nigeria Plateau State43 Cattle Isolation from kidney NR 5 strains isolated, 1 new serovar and
strain: serovar Nigeria, strain Vom
Nigeria Plateau State44 Rodents Organ survey (culture) 503 0.0%
Nigeria Plateau State44 Rodents Serosurvey (MAT 1:100) 105 44.8%
Mali Bamako61 Cattle (dairy) Serosurvey (MAT 1:100) 642 44.9%
Senegal Cap Vert region56 Rodents Serosurvey and organ survey 170 0.0%
Senegal Dakar57 Cattle Abattoir serosurvey (MAT 1:100) 433 20.8%
Senegal Dakar57 Sheep Abattoir serosurvey (MAT 1:100) 200 9.0%
Senegal Dakar57 Goats Abattoir serosurvey (MAT 1:100) 150 0.6%
Senegal Dakar57 Pigs Abattoir serosurvey (MAT 1:100) 66 4.5%
Central Africa
Cameroon Adamawa region68 Cattle Serosurvey (ELISA): estimation true
seroprevalence adjusting for diagnostic
test performance and study design
1377 from
146 herds
p(animal) = 0.304 (95% CI 0.276–0.332)
(30.4%)
p(herd) = 0.933 (95% CI 0.894–0.972)
p(withinherd) = 0.334 (95% CI 0.304–
0.364)
Cameroon Adamawa region161 Cattle Risk-factor analysis (based on
Scolamacchia et al., 201068
1377 from
146 herds
Risk factors: cattle >2 y OR 2.76 (95% CI
2.15–3.55); mixing herds at night OR
1.48 (95% CI 1.05–2.07)
Chad NR69 Dog Case report, MAT + ELISA 1
DRC Ituri Forest64 Duikers Serosurvey (MAT 1:100) 61 26.2%
East Africa
Djibouti NR104 Cattle, horses,
camels
Serosurvey (MAT) 31 84.0%
Ethiopia NR98 Dogs Serosurvey (RMAT) NR 0.0%
Ethiopia West and Southern99 Rodents Organ + serosurvey (MAT + culture) 376 0.0%
Ethiopia West and Southern99 Cattle Serosurvey (MaAT) 137 26.3%
Ethiopia West and Southern99 Sheep Serosurvey (MaAT) 31 0.0%
Ethiopia West and Southern99 Goats Serosurvey (MaAT) 36 16.7%
Ethiopia NR100 Cattle Serosurvey (MAT 1:100) 307 70.7%
Ethiopia NR100 Sheep Serosurvey (MAT 1:100) 159 43.3%
Ethiopia NR100 Goat Serosurvey (MAT 1:100) 93 47.3%
Ethiopia NR100 Camels Serosurvey (MAT 1:100) 78 15.4%
Ethiopia NR100 Pigs Serosurvey (MAT 1:100) 21 57.1%
Ethiopia NR100 Dogs Serosurvey (MAT 1:100) 12 8.3%
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Ethiopia NR100 Rodent Serosurvey (MAT 1:100) 6 0.0%
Ethiopia NR100 Horses Serosurvey (MAT 1:100) 34 91.2%
Ethiopia NR100 Monkeys Serosurvey (MAT 1:100) 24 0.0%
Ethiopia NR100 Birds Serosurvey (MAT 1:100) 24 0.0%
Kenya Nairobi, Kibera77 Rodents Organ survey (PCR) 237 18.3% (95% CI 13.5–24.0%)
Kenya NR78 Cattle Outbreak report (NR) 34 70.6% (24/34) affected, fed on a fresh
batch of hay
Kenya Countrywide79 Goats Serosurvey (NR) 898 16.2%
Kenya Nyandarua district73 Cattle Serosurvey (MAT 1:200) 326 34.0% (MAT 1:50: 49.0%)
Kenya Turkana district73 Cattle Serosurvey (MAT 1:200) 439 22.3% (MAT 1:50: 44.2%)
Kenya Nyandarua district73 Sheep and
goats
Serosurvey (MAT 1:200) 357 34.2% (MAT 1:50: 55.0%)
Kenya Turkana district73 Sheep and
goats
Serosurvey (MAT 1:200) 369 3.8% (MAT 1:50: 24.0%)
Kenya Countrywide80 Rhinoceroses Serosurvey (MAT 1:50) 58 15.5%
Kenya Countrywide81 Cattle Serosurvey (MAT 1:200) 2864 25.0%
Kenya Coast Province, Nyaza
Province82
Rodent Isolation and typing of new serovars 3 1. Tarassovi, serovar Kanana
2. Autumnalis, serovar Lambwe
3. Ballum, serovar Njenga
Kenya NR84 Bovine Serological survey NR ‘high incidence’ (NR)
Kenya Kiambu area85 Bovine Outbreak report NR NR
Kenya Countrywide86 Cattle Outbreak report NR Yearly outbreak reports concerning
hundreds of cattle
Kenya Nakuru district, Rift valley
province86
Cattle Outbreak report NR Outbreak on a farm – disease was later
spread to Nakuru, Nyandarua, Baringo,
Rumuruti, Thika and Naivasha
Kenya Kabete83 Cattle NR NR NR
Sudan Melut district60 Cattle Serosurvey (MAT 1:100) 195 54.0%
Sudan Melut district60 Wild mammals
(22 species)
Serosurvey (MAT 1:100) 717 9.8%
Sudan Melut district60 Wild birds
(14 species)
Serosurvey (MAT 1:100) 54 1.9%
Sudan Countrywide105 Cattle Serosurvey (MAT) 1142 15.3% (higher rates wetter areas)
Sudan Countrywide105 Goats Serosurvey (MAT) 30 13.3% (higher rates wetter areas)
Sudan Countrywide105 Rats Serosurvey (MAT) 56 23.3% (higher rates wetter areas)
Sudan Omdurman105 Cattle Organ survey (kidney
immunoﬂuorescence)
235 2.5%
Sudan NR162 Animal NR NR NR
Tanzania Central region163 Rodent Serosurvey (MAT 1:20) 350 17.7%
Tanzania Tanga city94 Cattle Serosurvey (MAT 1:160) 51 51.0% (95% CI 44.1–57.9%)
Tanzania Tanga region93 Cattle Serosurvey (MAT 1:160) 655
from 130
herds
Cattle: 30.3% (95% CI 26.7–33.9%);
herds: 58.5% (95% CI 49.5–67.1%)
Tanzania Morogoro164 Pigs Serosurvey (MAT 1:160) 385 4.4%
Tanzania Morogoro164 Pigs Urine survey (culture) 236 0.8%
Tanzania Countrywide89 Rodents Serosurvey (MAT 1:160) 537 1.9%
Tanzania Countrywide89 Cattle Serosurvey (MAT 1:160) 374 7.5%
Tanzania Countrywide89 Dogs Serosurvey (MAT 1:160) 208 37.5%
Tanzania Countrywide89 Cattle Urine survey (culture) 1021 0.7%
Tanzania East Usambara Mountains165 Cattle Serosurvey (MAT 1:160) 80 21.3%
Tanzania Morogoro166 Rodents Organ survey (PCR + culture + MAT) 27 15.0% (PCR), 7.4% (isolation), 0% (MAT)
Tanzania Tanga region92 Cattle Serosurvey (MAT) 230 10.8% (95% CI 7.15–15.62%)
Tanzania Morogoro167 Rodents Isolation + characterization isolates
(Sh9 + Sh25), Cross-agglutination
absorption test (CAAT) and DNA
ﬁngerprinting
2 NA
Tanzania Morogoro168 Cattle Isolation + typing L. kirschneri
CAAT + monoclonal antibodies, PCR
1 NA
Tanzania Central region169 Rodents Model of LS infection dynamics in
rodents
NA Strong seasonality in the force of
infection of humans with a peak
between January and April in
agricultural environments
In urban areas, the dynamics are more
stable, with a period of a high number
of infected animals from February to
July
Removal of animals by trapping will
have a greater impact on human LS
(instead of reducing suitability of
environment)
Uganda NR102 Dogs Serosurvey (MAT 1:200) 116 26.7% (95% CI 19.0–36.1%)
Uganda Queen Elizabeth and Bwindi
National Park170
Cattle
African buffalo
Cross-sectional serosurvey
ELISA IgG + IgM for L. hardjo
Cattle 92
Buffalo 92
Cattle: 29.4%
Buffalo: 42.4%
Uganda Queen Elizabeth and Bwindi
Impenetrable National Park103
African buffalo Serosurvey (MAT) 42 0.0%
Southern Africa
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Angola NR144 Rodents Organ survey (PCR + culture) 77 13.0% (PCR), 10.8% (culture, from 37)
Botswana Chobe district148 Banded
mongooses
Organ survey (PCR) 41 41.5% (95% CI 27.7–56.7%)
Botswana Chobe district148 Selous
mongoose
Organ survey (PCR) 1 100.0%
Botswana Tropic of Capricorn149 Cattle Abortion outbreak investigation, urine
+ serosurvey (culture + MAT 1:80)
47 67.5% MAT (27/40), 1/7 isolation of
serovar Pomona
Namibia Damaraland125 Rhinoceroses Serosurvey (MAT 1:100) 3 0.0%
Namibia Waterberg Plateau80 Rhinoceroses Serosurvey (MAT 1:50) 32 9.4%
Namibia Etosha National Park171 Impala Serosurvey (MAT 1:100) 27 0.0%
Malawi Countrywide147 Cattle Abattoir serosurvey (MAT 1:100) 275 21.4%
Mozambique Maputo151 Pigs Abortion outbreak investigation (MAT
serum foetus)
80 0.0%
South Africa Johannesburg106 Rodents Organ serosurvey 193 0.0%
South Africa Coastal regions108 Dogs Serosurvey (MAT 1:100) 530 4.7% (4.3 times more in stray dogs,
more risk in Eastern Cape and KwaZulu-
Natal)
South Africa KwaZulu-Natal109 Cattle Serosurvey (MAT) 2021 19.4% (95% CI 14.8–24.1%)
South Africa Durban, Cato Crest107 Rodents Serosurvey (LeptoTek Dri-Dot RDT) 221 10.0%
South Africa Durban, Cato Crest107 Rodents Serosurvey (PCR) 69 14.5%
South Africa Four National Parks80 Rhinoceroses Serosurvey (MAT 1:50) 182 26.4%
South Africa Mpumalanga Province110 Pigs Abortion outbreak investigation of a
farm; organ + serosurvey (kidney +
foetal culture + MAT 1:160)
52 serology
9 organs
17.0%
9/9 isolation serovar Pomona
South Africa Mpumalanga Province110 Cattle Serosurvey piggery (see above) (MAT
1:160)
170 52.0%
South Africa Mpumalanga Province110 Sheep Serosurvey piggery (see above) (MAT
1:160)
153 1.3%
South Africa Mpumalanga Province110 Horses Serosurvey piggery (see above) (MAT
1:160)
13 39.0%
South Africa Gauteng Province110 Pigs Abortion outbreak investigation of a
farm; organ + serosurvey (kidney +
foetal culture + MAT 1:160)
64 36.8% during outbreak, 0% after
outbreak
9/9 isolation of Pomona
South Africa Gauteng Province110 Cattle Serosurvey after abortion outbreak
(MAT 1:160)
19 58.0%
South Africa Gauteng Province110 Sheep Serosurvey after abortion outbreak
(MAT 1:160)
24 12.5%
South Africa Gauteng Province110 Dogs Serosurvey after abortion outbreak
(MAT 1:160)
6 50.0%
South Africa Gauteng Province110 Horses Serosurvey after abortion outbreak
(MAT 1:160)
6 0.0%
South Africa Gauteng Province110 Rodent Organ survey after abortion outbreak
(culture)
11 0.0%
South Africa Free State110 Cattle Outbreak investigation after death of
cows; serosurvey (MAT 1:100)
222 49.8% of herd, 54.0% of recently ill
animals
South Africa Free State110 Cattle Outbreak investigation after death of
cows; organ + urine survey (culture)
13 3/12 urine serovar Pomona
1/1 kidney serovar Pomona
South Africa Free State110 Pigs Outbreak investigation after death of
cows; organ + serosurvey (culture +
MAT 1:100)
36 45.0% (9/20) positive MAT
6/16 kidneys serovar Pomona
South Africa Free State110 Dogs Outbreak investigation after death of
cows; serosurvey (MAT 1:100)
8 0.0%
South Africa Free State110 Rodents Outbreak investigation after death of
cows; serosurvey (MAT 1:100)
8 0.0%
South Africa Countrywide111 Pigs Abattoir serosurvey (MAT 1:80) 5041 22.2%
South Africa Greater Pretoria area112 Dogs Serosurvey (MAT) 400 1.5%
South Africa Volksrust district113 Cattle Serosurvey (MAT 1:80) 860 3.0%
South Africa Kruger National Park114 Buffalo Serosurvey (MAT) 406 1.7% (6.6% inconclusive)
South Africa Northern Natal115 Wild mammals
(12 species)
Serosurvey (MAT 1:40) 50 12.0%
South Africa Transvaal116 Cattle Serosurvey (MAT) 170 52.0%
South Africa Transvaal116 Sheep Serosurvey (MAT) 152 1.0%
South Africa Transvaal116 Pigs Serosurvey (MAT) 52 17.0%
South Africa Transvaal116 Horses Serosurvey (MAT) 13 38.0%
South Africa Transvaal116 Dogs Serosurvey (MAT) 2 100.0%
South Africa Onderstepoort117 Cattle Serovar isolation and typing from cow
urine
1 NA
South Africa Transvaal118 Cattle Serovar isolation and typing from cow
urine after abortion cluster
1 NA
South Africa Countrywide119 Vervet
monkeys
Serosurvey (complement ﬁxation test) 50 8.0%
South Africa NR120 Pigs Outbreak investigation of an abortion
outbreak; organ + serosurvey (culture +
MAT 1:100)
250 62.1% MAT positive
6/10 isolation Canicola
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South Africa NR120 Dogs Outbreak investigation of an illness
outbreak; organ + serosurvey (culture +
MAT 1:100)
38 86.5% MAT positive, 1/1 isolation of
Canicola
Zambia NR145 Rodents Serosurvey (ELISA Leptospira rLipL32
antigen)
466 0.2%
Zimbabwe Harare + rural communities122 Dogs Serosurvey (ELISA IgG) 250 15.6% (95% CI 11.0–20.2%) (signiﬁcantly
higher prevalence in urban dogs)
Zimbabwe Mashonaland East Province123 Pigs Abstract + full text not available
Zimbabwe NR124 Wildlife Serosurvey (MAT) 992 4.6%
(Buffalo 6.0% (21/347), eland 10.8% (8/
74), wildebeest 16.7% (9/54), zebra
18.2% (2/11), white rhinoceroses 1.4%
(1/72), black rhinoceroses 4.9% (5/102))
Zimbabwe Harare121 Rodents Organ, urine + survey (culture + MAT
1:100)
437 62.5% MAT, 52 isolates (40 from
kidneys, 12 from urine)
Zimbabwe Zambezi Valley +
Escarpment125
Rhinoceroses Serosurvey (MAT 1:100) 60 63.0% (88.0% in riverside animals, 18.0%
in escarpment animals)
Zambia Lusaka126 Pigs Serosurvey (NR) 121 14.9%
Zimbabwe Urban areas127 Cattle Serosurvey (MAT 1:100) 2382 27.0% (signiﬁcantly higher in
commercial farming and purchase
areas)
Zimbabwe Harare (animals from
Mashonaland + Manicaland)129
Cattle Abattoir organ survey (culture) 480 10.4%
Zimbabwe Harare130 Cattle Isolation + typing by CAAT, monoclonal
antibody + restriction endonuclease
DNA analyses of new serovar found in
study by Feresu 1992129
1 NA
Zimbabwe Harare131 Bovine Isolation + typing by CAAT, monoclonal
antibody + restriction endonuclease
DNA analyses of new serovar found in
study Feresu 1992;129 CAA + RFLP
5 NA
Zimbabwe Harare132 Bovine Identiﬁcation of strains (Feresu
1992,129 1993,130 1994131) by CAAT
mAbs, RFLP and PCR
2 NA
Zimbabwe Harare133 Bovine Isolation + typing by CAAT, RFLP,
pulsed-ﬁeld gel electrophoresis of
genomic DNA of new isolates found in
study Feresu 1992129
4 NA
Zimbabwe Harare134 Bovine Isolation + typing by CAAT and RFLP of
new isolates found in study Feresu
1992129
2 NA
Zimbabwe Harare136 Bovine Isolation + typing by CAAT, RFLP, PCR of
new isolates found in study Feresu
1992129
1 NA
Zimbabwe NR137 Dogs NR 146 13.7% (19/146)
MAT, microscopic agglutination test; LS, leptospirosis; NR, not reported; RMAT, rapid microscopic agglutination test; MaAT, macroscopic agglutination test;
NA, not applicable; CAAT, cross-agglutinin absorption test; RDT, rapid diagnostic test; RFLP, restriction fragment length polymorphism; mAbs, mouse monoclonal antibodies.
Table 4
Miscellaneous environmental studies
Country Study site Type of
sample
Method Number of
samples
Prevalence Serogroup/
serovar
Other ﬁndings
South Africa Bruma, Rhodes
Park, Gilloolys
Farm,
Modderfontein,
Alexandra (part
Juksie River
catchment)106
Environmental
samples: water
and soil
Cross-sectional
environmental study from
10 different sites along
Juksie River in 2 years time
Nested PCR (Leptospira 16S
rDNA)
Water 77
Soil 79
Soil: 23.8% soil Rhodes Park +
Bruma; 9.5% soil Dobsonville,
Gilloolys + Modderfontein;
4.8% soil Alexandra Extension
Water: 14.3% water Bruma
Lake; 4.8% water
Modderfontein Dam
NR Soil vs. water p = 0.0018
(Chi-square 7.5;
1 degree of freedom)
NR, not reported.
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